Oragenics, Inc. (OGEN)
| Market Cap | 2.36M -52.8% |
| Revenue (ttm) | n/a |
| Net Income | -10.08M |
| EPS | -2.51 |
| Shares Out | 4.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,313 |
| Open | 0.4950 |
| Previous Close | 0.5000 |
| Day's Range | 0.4902 - 0.5229 |
| 52-Week Range | 0.4756 - 1.4500 |
| Beta | 1.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About OGEN
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen,... [Read more]
Financial Performance
Financial StatementsNews
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Suc...
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intra...
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital ...
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, wi...
ORAGENICS PROVIDES INVESTOR UPDATE
A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) Dear Fellow Shareholders, Since our last investor update, Oragenics has ...
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal del...
Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002
Oragenics (OGEN) announced that 2 patients and 8 study drug doses have been administered in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company’s lead candidate for the treatment…
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
SARASOTA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal d...
Oragenics receives audit opinion with going concern explanation
Oragenics (OGEN)announced that, as previously disclosed in its 2025 Annual Report filed on March 16, the audited consolidated financial statements contained an unqualified audit opinion from its indep...
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal d...
Oragenics files annual report on Form 10-K
Oragenics (OGEN) announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. In conjunction with…
Oragenics initiates Phase IIa clinical trial site activation
Oragenics (OGEN) announced it has completed the first site initiation visit for its Phase IIa clinical trial of ONP-002 in Australia. The visit marks the formal launch of clinical trial…
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-tar...
Oragenics explores potential acquisition of additional assets in CNS space
Oragenics (OGEN) announced that it is exploring discussions with third parties regarding the potential acquisition of additional assets in the central nervous system space, with a specific focus on br...
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal d...
Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia
Oragenics (OGEN) announced that it has received final Human Research Ethics Committee, HREC, approval in Australia to commence its Phase IIa clinical trial evaluating its lead drug candidate, ONP-002,...
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sites Potential first and only pharmacological treatment for the most prominent neurologi...
Oragenics previews targeted milestones for 2026
Oragenics (OGEN) previewed its targeted milestones for 2026. Oragenics is advancing its lead candidate ONP-002, a novel intranasal neurosteroid, through clinical studies as the potential first and onl...
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Austr...
Oragenics partners with Duck Flats Pharma to support FDA IND trial design
Oragenics (OGEN) announced it has engaged Duck Flats Pharma as its U.S. Investigational New Drug, IND, readiness and regulatory execution partner to support FDA-facing preparation and clinical trial d...
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy
Oragenics files $100M mixed securities shelf
16:13 EST Oragenics (OGEN) files $100M mixed securities shelf
Oragenics Q3 2025 Shareholder Update
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology...
Oragenics regains compliance with NYSE
Oragenics (OGEN) announced that it has regained full compliance with NYSE American’s continued listing standards and is positioning the company to focus exclusively on advancing its lead clinical prog...